$PEP

Deutsche Bank Downgrades PepsiCo to Hold From Buy, Adjusts Price Target to $138 From $155

Deutsche Bank downgraded PepsiCo from Buy to Hold, lowering its price target from $155 to $138. PepsiCo's stock is currently at $128.63, with a 5-day change of +0.37% and a year-to-date change of -0.86%.

Original reporting
Published Sep 28, 2026, 9:32 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 28, 2026, 9:49 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$PEP
Bearish
high confidence
Mentioned
$PEP
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$PEPBearishMed
01

Why it matters

The downgrade signals potential earnings pressure or valuation concerns, likely prompting short‑term sell pressure.

02

Market read

Analyst rating changes are a key driver for short‑term price moves in large‑cap stocks like PepsiCo.

03

What to watch

Recent cost‑saving initiatives and stable cash flow may mitigate the impact of the lower target.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

Deutsche Bank adjusted its rating and target for PepsiCo, reflecting a more cautious outlook.

Company-level read

Ticker impact

$PEPBearishHigh confidence
Context

Deutsche Bank downgraded PepsiCo to Hold and cut the price target to $138 from $155.

Expected impact

likely downside pressure as investors price in the reduced target

Evidence & confidence

The downgrade is a fresh analyst action with a concrete new price target, prompting traders to consider selling or reducing exposure.

Market effects

May weigh on the consumer staples sector as peers could face similar scrutiny.

Primarily U.S. market impact; limited effect on other regions.

Modest global relevance, confined to investors tracking large-cap consumer stocks.

Counterpoint

The downgrade could be premature if PepsiCo's fundamentals remain strong, presenting a buying opportunity.

Key entities

  • PepsiCo

    Global food and beverage conglomerate.

  • Deutsche Bank

    Investment bank providing the downgrade and new price target.

Related articles

$PEPMed

Deutsche Bank cuts Pepsico stock rating on North America struggles

Deutsche Bank downgraded Pepsico (PEP) to Hold from Buy, lowering its price target to $138 from $155. Analyst Steve Powers cited struggles in North America, particularly in the Frito-Lay and Pepsi Beverages divisions. The stock trades at $128.63, near its 52-week low. Other analysts have mixed views, with BNP Paribas Exane lowering its target to $161 but maintaining an Outperform rating, while TD Cowen kept a Hold rating with a $145 target. Pepsico is set to release Q3 earnings on October 8.

$NKEHigh

Why Did NKE, PEP, FRMI Stocks Dip To 52-Week Lows Last Week?

Nike (NKE) fell to a 52-week low after a BofA downgrade, citing earnings risks and a longer-than-expected turnaround. PepsiCo (PEP) also hit a 52-week low due to rising costs and weak North American sales, though it closed higher. Fermi (FRMI) dropped amid cash burn and CEO disputes. NKE, PEP, and FRMI stocks are down 43%, 9%, and 49% YTD, respectively.

$TSLAMedAI 8/10

Microsoft, PepsiCo Back Record 2,500-Truck Tesla Semi Order

ZET SCALE, backed by Microsoft and PepsiCo, ordered 2,500 Tesla electric trucks, the largest U.S. order of its kind. Tesla is the primary supplier, with Kenworth, RIDE, and Volvo as secondary options. The alliance aims to scale to 10,000 trucks, using pooled demand to reduce financial risk. The trucks will operate across ten major U.S. freight hubs.

$NVOMed

GLP-1 prices are falling but a big change could affect what you pay

Novo Nordisk will cut U.S. list prices for Ozempic and Wegovy by 34% and 50% respectively, starting in 2027. Eli Lilly's new GLP-1 pill, Foundayo, was approved by the FDA. Prices vary by insurance coverage. Some employers, like PepsiCo and Cigna, are ending weight loss drug coverage. New drugs from Lilly, Novo Nordisk, and Amgen are in development.